{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:56:13Z","timestamp":1775238973102,"version":"3.50.1"},"reference-count":22,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2024]]},"DOI":"10.3960\/jslrt.24011","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T22:11:25Z","timestamp":1722377485000},"page":"177-182","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the effects of MCVAC conditioning regimen followed by autologous hematopoietic stem cell transplantation in patients with relapsed and refractory Hodgkin lymphoma: A single-institution retrospective study"],"prefix":"10.3960","volume":"64","author":[{"given":"Ken","family":"Naganuma","sequence":"first","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoe","family":"Anan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"},{"name":"Department of Transfusion and Cell Therapy, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kizaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Momose","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihiro","family":"Higashi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Tabayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Ohshima K, Suzumiya J, Kikuchi M. The World Health Organization classification of malignant lymphoma: incidence and clinical prognosis in HTLV-1-endemic area of Fukuoka. Pathol Int. 2002; 52: 1-12.","DOI":"10.1046\/j.1440-1827.2002.01308.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Muto R, Miyoshi H, Sato K <i>et al.<\/i> Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification. Cancer Med. 2018; 7: 5843-5858.","DOI":"10.1002\/cam4.1805"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Shah GL, Moskowitz CH. Transplant strategies in relapsed\/refractory Hodgkin lymphoma. Blood. 2018; 131: 1689-1697.","DOI":"10.1182\/blood-2017-09-772673"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Canellos GP, Abramson JS, Fisher DC, LaCasce AS. Treatment of favorable, limited-stage Hodgkin\u2019s lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol. 2010; 28: 1611-1615.","DOI":"10.1200\/JCO.2009.25.3260"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Straus DJ, D\u0142ugosz-Danecka M, Connors JM <i>et al.<\/i> Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021; 8: e410-e421.","DOI":"10.1016\/S2352-3026(21)00102-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Chen YB, Lane AA, Logan B <i>et al.<\/i> Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015; 21: 1046-1053.","DOI":"10.1016\/j.bbmt.2015.02.005"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Sugimoto M, Ito S, Mashima K <i>et al.<\/i> Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ann Hematol. 2016; 95: 1513-1519.","DOI":"10.1007\/s00277-016-2740-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Yui S, Wakita S, Nagata Y <i>et al.<\/i> Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative study. Asia Pac J Clin Oncol. 2023; 19: 136-148.","DOI":"10.1111\/ajco.13780"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Koresawa-Shimizu R, Suzuki R, Uehara Y <i>et al.<\/i> Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed\/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopoietic and Cellular Therapy Registry. Bone Marrow Transplant. 2024; 59: 125-127.","DOI":"10.1038\/s41409-023-02118-w"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Kato J, Mori T, Yokoyama K <i>et al.<\/i> Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma. Bone Marrow Transplant. 2011; 46: 923-928.","DOI":"10.1038\/bmt.2010.243"},{"key":"11","unstructured":"11 Sekiguchi Y, Wakabayashi M, Takizawa H <i>et al.<\/i> Retrospective analysis of 20 patients with DLBCL who received MCVAC followed by autologous peripheral blood stem cell transplantation. Gan To Kagaku Ryoho. 2019; 46: 1265-1273."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013; 48: 452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Driessen J, Tonino SH, Moskowitz AJ, Kersten MJ. How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents. Hematology Am Soc Hematol Educ Program. 2021; 2021: 240-246.","DOI":"10.1182\/hematology.2021000311"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Pfreundschuh MG, Rueffer U, Lathan B <i>et al.<\/i> Dexa-BEAM in patients with Hodgkin\u2019s disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin\u2019s Disease Study Group. J Clin Oncol. 1994; 12: 580-586.","DOI":"10.1200\/JCO.1994.12.3.580"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Yu TC, Yu SC, Wang RC <i>et al.<\/i> Investigating early progression of Hodgkin lymphoma in a two-center analysis. J Formos Med Assoc. 2022; 121: 1215-1222.","DOI":"10.1016\/j.jfma.2021.12.025"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Moskowitz CH, Nademanee A, Masszi T <i>et al.<\/i> Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 385: 1853-1862.","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Takaue Y, Watanabe T, Hoshi Y <i>et al.<\/i> Effectiveness of high-dose MCNU therapy and hematopoietic stem cell autografts treatment of childhood acute leukemia\/lymphoma with high-risk features. Cancer. 1991; 67: 1830-1837.","DOI":"10.1002\/1097-0142(19910401)67:7<1830::AID-CNCR2820670703>3.0.CO;2-E"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Kameoka Y, Akagi T, Murai K <i>et al.<\/i> Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma. Int J Hematol. 2018; 108: 510-515.","DOI":"10.1007\/s12185-018-2508-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Yeh ET, Tong AT, Lenihan DJ <i>et al.<\/i> Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004; 109: 3122-3131.","DOI":"10.1161\/01.CIR.0000133187.74800.B9"},{"key":"20","unstructured":"20 Sekiguchi Y, Takizawa H, Wakabayashi M <i>et al.<\/i> Fatal veno-occlusive disease (VOD)\/sinusoidal obstruction syndrome (SOS) developing after high-dose chemotherapy combined with autologous peripheral blood stem cell transplantation for recurrent malignant lymphoma: report of a case. Int J Clin Exp Med. 2017; 10: 7189-7198."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Eladl AE, Satou A, Elsayed AA <i>et al.<\/i> Clinicopathological study of 30 cases of peripheral T-cell lymphoma with Hodgkin and Reed-Sternberg-like B-cells from Japan. Am J Surg Pathol. 2017; 41: 506-516.","DOI":"10.1097\/PAS.0000000000000813"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Huang Y, Hu S, Larson DP <i>et al.<\/i> Composite classic Hodgkin lymphoma and follicular lymphoma: A clinicopathologic study of 22 cases with review of 27 additional cases in the literature. Am J Surg Pathol. 2022; 46: 793-800.","DOI":"10.1097\/PAS.0000000000001828"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/3\/64_24011\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T05:06:21Z","timestamp":1727499981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/3\/64_24011\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.24011","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"24011"}}